How TIB200 works

TIB200 is a topical 10% ibuprofen gel for pain relief that utilises Futura's DermaSys® technology. DermaSys® enables a fast onset of relief at the site of pain and the potential for improved patient benefit by reducing the dosing frequency from three to four times daily to twice daily.

Futura's unique DermaSys® technology enables targeted delivery of ibuprofen through the skin to the site of action and sustained release.

TPR100 Diagram


Compelling clinical data showing efficacy and safety profile

In early in vitro studies and in an in vivo clinical study DermaSys® showed significant superiority in terms of skin penetration of ibuprofen. TIB200, a topical gel combining the well-known analgesic ibuprofen with the DermaSys® delivery system, has been shown to achieve up to twenty times higher penetration through human skin compared against other commercially available topical ibuprofen gels.

In a clinical study to assess the efficacy and safety against a market-leading ibuprofen gel, oral ibuprofen as well as a placebo gel, TIB200 not only achieved its primary efficacy endpoint against placebo but also outperformed both the topical and oral comparators.

Improved permeation compared to market leaders at same dosage

Improved permeation compared to market leaders at same dosage


Commercial strategy

TIB200 has attracted considerable interest from pharmaceutical and consumer healthcare companies. We continue to be in discussions regarding potential regional licensing deals. EU regulators require a placebo controlled efficacy study prior to EU regulatory filing. Futura made the strategic decision to require partner commitment before progressing this clinical expenditure.